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Avahan and the cost-eﬀ ectiveness of “prevention 
as prevention” 
Avahan, the India AIDS Initiative funded by the Bill & 
Melinda Gates Foundation, is one of the largest HIV 
prevention programmes targeted to populations at 
high risk of infection. The initiative operated across 
22 districts and committed US$258 million from 2004 
to 2009, reaching 154 425 individuals. Through work 
with non-governmental organisations (NGOs), and a 
focus on peer-led interventions, it oﬀ ered a package of 
services that included risk-reduction education, access 
to condoms, screening and treatment for sexually 
transmitted infection, and referral to clinical services 
as appropriate. Avahan was a full-scale, real-world 
test of the generally accepted principle that focused 
prevention in high-risk groups, particularly in the 
context of a concentrated epidemic, can substantially 
and eﬃ  ciently reduce the incidence of HIV infection.1 
Although these ﬁ ndings are not novel, showing them in 
the context of a programme of this scale is important 
and should increase the conﬁ dence of global health 
decision makers that investments in thoughtfully 
designed, scaled-up prevention programmes can yield 
large eﬀ ects on health. 
Much of the focus of expert and public attention 
has been on HIV treatment, including test and 
treat (ie, treatment as prevention) strategies. This 
is understandable. Treatment for HIV has become 
extraordinarily eﬀ ective, costs have dropped substantially 
during the past two decades, and the potential for 
antiretroviral therapy to reduce community viral load 
and transmission was shown in the groundbreaking 
HPTN 052 trial2,3 in 2011. Against this background, the 
publication of these important and positive ﬁ ndings 
on the beneﬁ ts and economic attractiveness of Avahan 
serves as a welcome reminder that so-called prevention 
as prevention can be extremely cost-eﬀ ective. 
Treatment programmes designed to reach the general 
population might be politically more palatable than those 
targeted at individuals at high risk of infection, including 
sex workers, intravenous drug users, and men who 
have sex with men. The evaluation of Avahan reinforces 
previous understanding that serving the health-care 
needs of these marginalised groups is often the most 
direct and eﬃ  cient way to curb the HIV epidemic.
Prevention of HIV transmission among groups at 
high risk of infection can be very cost eﬀ ective. The 
most important ﬁ nding of this study is that the package 
of preventive services delivered by Avahan yields an 
incremental cost of $46 per disability-adjusted life-year 
(DALY) averted. This cost-eﬀ ectiveness study indicates 
that Avahan-style interventions are an extraordinarily 
good use of public health funds, roughly on par with 
the provision of insecticide-treated bednets to prevent 
malaria; diarrhoeal disease prevention with the promotion 
of hygiene practices; volunteer paramedic training 
in emergency care; and the provision of childhood 
immunisation against tuberculosis, diphtheria, polio, and 
measles;4 and cost far less than the $597–833 per DALY 
averted or life-year gained cost-eﬀ ectiveness of other HIV 
treatment programmes in low-income countries.5–7 
Particularly encouraging is the fact that the study 
included a comprehensive account of the costs 
involved. Rather than being conﬁ ned to the level of 
service delivery, the study analysis included Avahan 
programme costs at the state and national levels, such 
as for programme management, capacity building, and 
community supply costs. One of the most important 
ﬁ ndings of this study is that these programme costs 
often ignored in cost-eﬀ ectiveness analyses exceeded 
those of service delivery by a wide margin. Avahan cost 
$109 per person at the NGO level compared with a 
programme cost of $327 per person. The importance of 
costs above the service delivery level have been noted 
in other studies.5 Although  this type of data collection 
takes more eﬀ ort, because the programme costs are 
such a large part of the total, the estimation of these 
programme management level costs, should become 
standard practice in cost-eﬀ ectiveness analyses. This 
study showed a substantial economy of scale in the 
delivery of HIV prevention. Although unsurprising, 
this result provides assurance that preventive HIV 
transmission programmes, when implemented on 
a suﬃ  ciently large scale, can have an eﬀ ect on the 
epidemic that will yield greater, not reduced, returns. 
Another striking ﬁ nding in this study is the wide 
variation in unit costs of $24–594 per person among the 
diﬀ erent service delivery sites and districts. These large 
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variations in unit cost have been seen elsewhere.8,9 An 
important question that this study was not designed to 
address pertains to the portion of this variation that is 
due to unavoidable diﬀ erences in costs incurred at the 
diﬀ erent sites, and what portion can be attributed to 
the diﬀ erences in personnel management, procurement 
practices, and other factors that could be addressed by 
programme administrators. To understand the drivers 
of this variation in unit costs and identify strategies 
to address such avoidable ineﬃ  ciencies is the cutting 
edge of global health economics inquiry. Irrespective of 
how cost eﬀ ective an intervention is overall, improved 
eﬃ  ciency (without sacriﬁ cing quality) means more 
money is available to save more lives.
An unavoidable, but relevant, shortcoming of the 
study design is the absence of concurrent control groups. 
The Avahan study, instead, compared results from the 
22 districts evaluated with a no-Avahan counterfactual 
scenario under the assumption of continued trends in 
condom use and other risk behaviours previously seen 
in these districts. However, with an incremental cost of 
$46 per DALY averted, there is much room for error in 
cost estimation before the positive economic outcomes 
predicted by this study can be called into question. In 
an era of either level spending or decreased real global 
spending on HIV therapy, the Avahan experience argues 
powerfully for commitment to so-called prevention as 
prevention even as strategies of treatment as prevention 
are being formulated.
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